Compare Abbott Laboratories (ABT) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.13. The key difference: Abbott Laboratories pays a 2.63% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | QDTY | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $46.71 |
52-Week Low | $82.57 | $36.57 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
QDTY trades at $41.16, up 1.66% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The stock exhibits weekly dividend distributions, with recent payouts ranging from $0.22 to $0.32. Support and resistance levels are clustered near the current price, indicating potential volatility. Recent news focuses heavily on dividend announcements from YieldMax ETFs, with minimal coverage of broader business performance or financial results.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Investment opportunity hinges on dividend yield sustainability, but risks include absence of earnings visibility and bearish technical pressure. Key catalysts for reversal would require positive earnings surprises or upward analyst revisions, which are currently unavailable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
